Public annual accounts

APO-PHARMAN financials

Name: APO-PHARMAN financials
Creator: Upswitch
License: https://www.upswitch.app/terms-and-conditions

A multi-period view of the public annual-account figures reported for APO-PHARMAN, with comparable measures and links to available source documents.

Company overview

Registry number

0892860848

Fiscal coverage

2024–2025

Public sources

cbso_bulk

Data updated

Jul 27, 2026

Financial evidence

Latest movements for APO-PHARMAN

2025 versus 2024

Operating line: €252,575
EBITDA: €173,286
Total assets: €1,306,700
Equity: €422,116

EBITDA margin +68.6% · Equity ratio +32.3%

Multi-year filings

Filed annual accounts by fiscal year

Public regulator-filed figures across 2 years.

Source: NBB/CBSO

Fiscal year	Gross margin	EBITDA	Total assets	Equity	Filing
202531 Dec 2025	€252,575	€173,286	€1,306,700	€422,116	-
202431 Dec 2024	€274,496	€202,462	€1,281,450	€360,791	-

Gross margin line from gross margin (abbreviated schema). This is not reported turnover, so it is not used as a public valuation base.EBITDA basis: operating profit plus full add-backs.

Figures reproduce public filings and may use country-specific accounting definitions. They are not audited by Upswitch.

Public company datasets

Explore the underlying reports

Valuation

2 valuation checkpoints · 2024 to 2025 · Method family

Open report